湿疹及皮炎

20053103咪唑斯汀治疗皮炎湿疹68例临床分析/段民录(西安电力中心医院皮肤科)∥中国皮肤性病学杂志.-2005,19(6).-380~381随机分为两组,咪唑斯汀组68例口服咪唑斯汀10mg,氯雷他定组50例口服氯雷他定10mg,均1次/d。咪唑斯汀治疗急慢性湿疹和异位性皮炎3周有效率为90.7%,氯雷他定为60.0%。两组差异有显著性(P<0.01),咪唑斯汀与氯雷他定对接触性皮炎的1周有效率均为100%,差异无显著性(P>0.05)。表2参2(余春艳)20053104易菲莎治疗皮炎湿疹130例/周英芹(江苏建湖县疾控中心),於如军∥皮肤病与性病.-2005,27(2).-24均外用易菲莎,早晚各1次,1周为1…     

咪唑斯汀联合他克莫司软膏治疗颜面再发性皮炎疗效观察

目的观察他克莫司软膏治疗颜面再发性皮炎的疗效。方法将90例患者分两组,治疗组60例,口服咪唑斯汀10mg,1次/d,外用0.1%他克莫司软膏,2次/d,连用2周;对照组30例,口服咪唑斯汀10mg,1次/d,连用2周。结果治疗组有效率88.3%,对照组为63.3%,两组比较差异有显著性意义(P<0.01)。结论咪唑斯汀联合他克莫司软膏治疗颜面再发性皮炎疗效较好。     

咪唑斯汀治疗慢性荨麻疹的随机双盲研究

目的 评价咪唑斯汀治疗慢性荨麻疹的疗效和安全性,并与氯雷他定进行比较。方法 多中心、随机双盲、平行对照临床试验。结果 5个研究中心共入选慢性荨麻疹患者213例,纳入疗效分析共206例,其中咪唑斯汀组104例,氯雷他定组102例。治疗结束时,咪唑斯汀组总有效率(痊愈+显效)为80.8%,氯雷他定组为74.5%,两组差异无显著性(χ²=1.16,P=0.28)。咪唑斯汀组于治疗后第1周时,对控制风团大小、每周发作次数及直观模拟标尺法(VAS)瘙痒程度平均值明显优于对照组,两组差异均有显著性(P=0.05,P=0.03和P=0.02)。至第2、4周时,两组间比较差异无显著性(P>0.05)。咪唑斯汀组不良事件发生率为28.6%,对照组为25.5%,差异无显著性(χ²=0.25,P=0.62)。结论 口服咪唑斯汀或氯雷他定10mg/d治疗慢性荨麻疹疗效相似,但咪唑斯汀似乎比氯雷他定组起效更快,两组不良事件发生率及表现无明显差异。     

咪唑斯汀联合30%尿素霜外用治疗结节性痒疹疗效观察

目的观察咪唑斯汀联合30%尿素霜外用治疗结节性痒疹的疗效。方法观察组患者口服咪唑斯汀10mg,对照组患者口服氯雷他定10mg,均1次/d;两组皆联合30%尿素霜外用,2次/d,连续治疗28天。结果观察组有效率为81.25%,对照组为51.43%,两组比较差异有显著性(P<0.05)。结论咪唑斯汀合并30%尿素霜外用治疗结节性痒疹临床疗效好,不良反应小。     

3种抗组胺药治疗慢性特发性荨麻疹的临床研究

目的:评价第2代抗组胺药咪唑斯汀、西替利嗪、氯雷他定治疗慢性特发性荨麻疹的疗效和安全性。方法:采用随机开放平行对照的方法,对96例慢性特发性荨麻疹患者进行随机分组,分别予以咪唑斯汀10mg、西替利嗪10mg、氯雷他定10mg,均每日1次口服,观察治疗第14天、第28天的临床疗效及停药1周后的复发率。结果:三者治疗慢性特发性荨麻疹第14天和第28天的有效率分别为:咪唑斯汀组90.0%和96.7%,西替利嗪组85.3%和94.2%,氯雷他定组90.6%和93.8%,三者之间差异无显著性(P>0.05)。停药1周后的复发率,咪唑斯汀组为40.0%,西替利嗪组为35.3%,氯雷他定组为28.1%。整个试验过程中均无明显严重不良反应出现。结论:咪唑斯汀、西替利嗪和氯雷他定治疗慢性特发性荨麻疹临床疗效好,安全性高,在改善临床症状及控制复发方面各有所长。     

润燥止痒胶囊联合咪唑斯汀缓释片治疗慢性湿疹疗效观察

目的观察润燥止痒胶囊联合咪唑斯汀治疗慢性湿疹的临床疗效。方法将80例临床确诊的慢性湿疹患者随机分为两组,治疗组40例口服润燥止痒胶囊4粒,3次/d,同时口服咪唑斯汀缓释片10mg,外用复方薄荷脑软膏,2次/d;对照组40例口服咪唑斯汀缓释片10mg,外用复方薄荷脑软膏,2次/d;连续治疗4周,根据评分标准进行疗效比较。结果治疗组有效率为87.5%,对照组为67.5%。两组有效率差异有显著性(P<0.05)。结论润燥止痒胶囊联合咪唑斯汀可有效治疗慢性湿疹。     

咪唑斯汀与地氯雷他定治疗慢性荨麻疹的随机单盲对照临床研究

目的:观察咪唑斯汀治疗慢性荨麻疹的疗效和安全性,并与地氯雷他定进行比较。方法:采用随机开放单盲对照方法,对78例慢性荨麻疹病例进行临床研究,治疗组给予口服咪唑斯汀10 mg,1天1次,持续14天,对照组给予口服地氯雷他定5 mg,1天1次,持续14天。结果:治疗组总有效率89.74%,对照组总有效率84.62%,差异无统计学意义(P>0.05),两组均未发现严重的药物不良反应。结论:咪唑斯汀治疗慢性荨麻疹安全有效,可作为治疗慢性荨麻疹的新选择。     

地氯雷他定与咪唑斯汀治疗慢性荨麻疹的疗效和安全性比较

目的 :评价地氯雷他定与咪唑斯汀比较治疗慢性荨麻疹的临床疗效和安全性。方法 :采用随机对照临床试验 ,试验组每日口服地氯雷他定 5mg,疗程 1 4d;对照组每日口服咪唑斯汀 1 0mg,疗程 1 4d。结果 :共治疗 94例 ,试验组 49例 ,对照组 45例。患者主、客观症状观察项目平均积分于服药第 7、1 4天均有下降 ,但两组比较均无统计学意义。治疗后第 1 4天总有效率为试验组 85 7% ,对照组 82 2 % ,两组比较差异无显著性 (P >0 0 5 )。不良反应发生率试验组为 1 0 2 % ,对照组为 1 3 3 % ,两组比较差异无显著性 (P >0 0 5 )。两组用药前后血尿常规、肝肾功能、心电图均无有意义的变化。结论 :地氯雷他定和咪唑斯汀都是治疗慢性荨麻疹安全有效的药物     

地氯雷他定治疗慢性荨麻疹疗效观察

目的 :观察地氯雷他定治疗慢性荨麻疹的疗效和安全性。方法 :采取随机对照临床试验 ,试验组每日口服地氯雷他定 5mg,疗程 2周 ;对照组每日口服咪唑斯汀 1 0mg,疗程 2周。结果 :共治疗1 5 6例 ,试验组 81例 ,对照组 75例 ,试验组总有效率为 88 9% ,对照组为 86 6% ,两组总有效率比较差异无显著性 (P >0 0 5 ) ;不良反应发生率试验组为 1 0 9% ,对照组为 9 3 % ,两组比较差异无显著性 (P>0 0 5 )。结论 :地氯雷他定是一种治疗慢性荨麻疹较安全有效的药物。     

咪唑斯汀联合复方甘草酸苷治疗慢性荨麻疹的疗效观察

目的探讨咪唑斯汀联合复方甘草酸苷治疗慢性荨麻疹的疗效和安全性。方法 143例患者随机分为三组。治疗组53例,口服复方甘草酸苷胶囊50mg3次/d,同时每晚口服咪唑斯汀缓释片10mg,1次/d;对照Ⅰ组47例单用咪唑斯汀缓释片;对照Ⅱ组43例单用复方甘草酸苷胶囊。两对照组用药方法均同治疗组,三组均连续治疗4周判效。结果治疗组有效率96.23%,对照Ⅰ组为59.57%,对照Ⅱ组为48.84%。治疗组有效率与两对照组比较差异均有显著性(P均0.01),两对照组有效率差异无显著性(P0.05)。三组均无明显不良反应。结论复方甘草酸苷联合咪唑斯汀治疗慢性荨麻疹疗效好、安全性高。     

816例皮肤点刺试验过敏原结果分析

目的 探讨特应性皮炎、慢性荨麻疹、慢性湿疹常见过敏原的可能致病情况.方法 用标准变应原液在前臂屈侧皮肤进行皮肤点刺试验,分别用0.1%组胺和0.9%氯化钠液作阳性和阴性对照,统计分析采用x2检验.结果 尘螨(屋尘螨+粉尘螨)的阳性率最高,达50.0%～78.6%,其次为动物毛,达7.1%～21.4%,霉菌的阳性率也较高,达7.1%～14.3%,并且这3种变应原在3种疾病间的阳性率差异均有统计学意义(P＜0.01),以特异性皮炎的阳性率最高.食物组过敏原中虾的阳性率(6.6%～14.3%)最高,但在3种疾病间的阳性率差异无统计学意义(P＞0.05);金枪鱼在慢性荨麻疹中的阳性率(9.5%)较高,鸡蛋、牛奶、芹菜在特异性皮炎中的阳性率(7.1%～14.3%)较高,这4种变应原在3种疾病间的阳性率差异均有统计学意义(P＜0.05).结论 吸入组过敏原是慢性过敏性皮肤病的常见过敏原,尘螨为首要过敏原,以特异性皮炎的阳性率为最高.     

Interrelationship between biliary dyskinesia and chronic urticaria, chronic eczema and atopic dermatitis

Interrelationships between biliary dyskinesia and chronic urticaria, chronic eczema and atopic dermatitis have been studied in 210 biliary dyskinesia patients and 60 normal subjects. Incidences of chronic urticaria, chronic eczema and atopic dermatitis were found more frequently in biliary dyskinesia patients than normal subjects. Skin symptoms of these chronic urticaria, chronic eczema and atopic dermatitis cases showed significant normalization with improved gallbladder contraction rate. COMT inhibitor therapy and fat restriction were more effective for the skin symptoms and for prolonging the interval before recidivation or exacerbation of these allergic diseases than conservative therapy.     

0.05%地奈德乳剂治疗内源性湿疹的临床研究

目的　评价 0 .0 5 %地奈德乳剂治疗内源性湿疹包括特应性皮炎 3周的疗效和安全性。方法　入组包括特应性皮炎在内的内源性湿疹 84例 ,采用随机、双盲、基质对照、平行组对比研究 ,受试者外涂药物于受累区域 ,2次 /d ,连续治疗 3周。结果　试验组靶皮损总积分 (TSS)由治疗前 8.3 1± 1.85降至 1.19± 1.69,TSS改善 84.99% ;对照组TSS由 8.43± 1.67降至 3 .10± 2 .2 4,TSS改善 63 .5 4%。试验组与对照组靶皮损各项观察指标均得到改善 ,但试验组的改善优于对照组。总体改善评价试验组总有效率为 80 .95 % ,对照组为 5 2 .3 8% ,两组比较差异有显著性 (P <0 .0 5 )。　结论　 0 .0 5 %地奈德乳剂治疗内源性湿疹的临床治愈率、总体疗效优于基质 ,且不良反应发生率低 ,是一种安全有效的外用皮质类固醇激素。     

两种氯雷他定药物治疗湿疹、皮炎的成本效果分析

目的：对两种氯雷他定(百为坦和开瑞坦)治疗湿疹、皮炎的成本效果进行分析．方法：将患者分为两组，每组30例，分别服用百为坦和开瑞坦，除观察疗效外还进行成本效果分析。结果：两组疗效相当，均无明显的不良反应。但百为坦的治疗成本明显低于开瑞坦．结论：氯雷他定治疗湿疹、皮炎疗效高，安全性好。百为坦比开瑞坦治疗成本低。     

Correlation of nipple eczema in pregnancy with atopic dermatitis in Northern India: a study of 100 cases

BackgroundNipple eczema is a less common presentation of atopic dermatitis. No studies in the literature have correlated nipple eczema in pregnancy as a manifestation of atopic dermatitis.ObjectiveTo evaluate whether nipple eczema presenting in pregnancy is a manifestation of atopic dermatitis.MethodsThis was a prospective observational study including 100 women who presented with nipple eczema for the first time during pregnancy. The exclusion criteria were any patient with previous history of nipple eczema, those already on oral or topical treatment for atopic dermatitis or nipple eczema, and other disorders mimicking eczema. Patients were divided into two groups ‒ nipple eczema with atopic dermatitis and without atopic dermatitis. Demographic data, clinical features, total leukocyte count, differential leukocyte count, absolute eosinophil counts, and serum IgE levels were compared between the two groups to detect association between nipple eczema in pregnancy and atopic dermatitis.ResultsOut of 100 patients, 39 were diagnosed with atopic dermatitis, whereas 61 were ruled out to have any features suggestive of atopic dermatitis. There were no statistically significant differences in mean age, mean duration of symptoms, and serum IgE levels. In patients with atopic dermatitis, bilateral symptoms were noted more commonly than in patients without the disease, but this was statistically insignificant.Study limitationsLack of long term follow-up and no large studies in literature to compare results.ConclusionNipple eczema in pregnancy follows a similar pattern as in other age groups. The clinical profile of patients is similar in cases with and without atopic dermatitis.     

The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta‐analysis

Primary studies have presented conflicting results on the efficacy of Janus kinase (JAK) inhibitors in treating atopic dermatitis. Hence, it is important to determine the summary effect of JAK inhibitors in order to guide the clinical application of this potentially beneficial drug. To determine the efficacy of JAK inhibitors in treating atopic dermatitis in all age groups. A systematic review with meta‐analyses of randomized controlled trials (RCTs) reporting on the effect of JAK inhibitors on the signs and symptoms of atopic dermatitis were conducted. Six electronic databases, registries, and search engines (PubMed, Cochrane Central Register of Controlled Trials [CENTRAL], Google Scholar, ScienceDirect, Clinical.gov, and WHO ICTRP) were searched from inception to September, 2019. The search terms include “atopic dermatitis,” “eczema,” and “Janus kinase inhibitor.” The search was restricted to humans. A total of 413 studies were identified through the database search and hand‐searching. After the selection process, five RCTs were included in this systematic review. A meta‐analysis of three studies showed that JAK inhibitors were effective in reducing Eczema Area and Severity Index (P = .0001) and pruritus scores (P = .0001). JAK inhibitors appear to be effective in treating atopic dermatitis. Future studies should aim to evaluate its cost‐effectiveness and availability to patients especially in developing countries.     

Hand eczema: an evaluation of the frequency of atopic background and the difference in clinical pattern between patients with and without atopic dermatitis

In a prospective study of 63 patients with long-lasting hand eczema, a diagnosis of atopic dermatitis could be established in 49%. Comparison between patients with atopic dermatitis and those without atopic dermatitis showed that the hand eczema pattern differed very little between the groups. Hyperlinearity was significantly more common in the palms of the patients with atopic dermatitis.     

Hand eczema in patients with history of atopic manifestations in childhood

A follow-up study of two groups of individuals aged 24-44 years, with a history of severe and moderate atopic dermatitis in childhood (n = 549 and 406 respectively), showed that the most common site of atopic dermatitis was the hands. The prevalence of hand eczema in the two groups was 41% and 25% respectively. The corresponding figure for a group of 222 individuals with respiratory allergy, but not atopic dermatitis in childhood, was 5%, and for a control group (n = 199), without family or personal atopy, 4%. In all four groups the majority of the patients had mild to moderate hand eczema. The fingers were the most common site in all groups. In 69%, 55%, 36% and 12% respectively, hand eczema was found simultaneously with other eczematous manifestations. Irritants were considered by 71-96% in the four groups to aggravate the hand eczema. Contact with various food substances, particularly proteins, was regarded by 38%, 43%, 30% and 9% as an eliciting/aggravating factor. Dust was looked upon as an eliciting/aggravating factor by 25% and 20% of the individuals in the two groups with atopic dermatitis in childhood, but by no one in the control group.     

Impact of acute stress on itch sensation and scratching behaviour in patients with atopic dermatitis and healthy controls

Patients with atopic dermatitis (eczema) often report that stress is a major factor to worsen their itchy skin. This study investigated the effects of acute stress on itch, urge to scratch, and scratching behavior in subjects with atopic dermatitis compared to healthy controls. Stress was created in a standardized way using the Trier Social Stress Test (TSST), where subjects were asked to perform a public speaking task and mental arithmetic. In a second control visit, instead of being stressed, subjects watched a non-stressful video of landscape scenes. Both subjects with atopic dermatitis and healthy subjects reported feeling stressed after the TSST. Interestingly, atopic dermatitis subjects who were more sensitive to stress also had higher eczema severity. Before and after the TSST or landscape video, cowhage (a plant that causes itch) was applied to the arm of each subject. Patients with atopic dermatitis reported less itch from cowhage and less urge to scratch after they had been stressed by the TSST. However, despite reporting less itch, they actually scratched their limbs significantly more when they were stressed. Healthy individuals did not have any difference in itch, urge to scratch, or scratching behavior in the stressful condition compared to the control landscape video condition. This study shows that acute stress can affect itch and scratching differently in chronic itch patients compared to healthy individuals. Stress led to more scratching in those with atopic dermatitis. Over time, this response to stress could lead to increased skin damage from scratching and therefore worse eczema and itch.